Diagnosis and Treatment of Community-Acquired Pneumonia

M. NAWAL LUTFIYYA, PH.D., ERIC HENLEY, M.D., M.P.H., and LINDA F. CHANG, PHARM.D., M.P.H., B.C.P.S.
University of Illinois College of Medicine at Rockford, Rockford, Illinois
STEPHANIE WESSEL REYBURN, M.D., M.P.H., *Mayo School of Graduate Medical Education, Rochester, Minnesota*

Patients with community-acquired pneumonia often present with cough, fever, chills, fatigue, dyspnea, rigors, and pleuritic chest pain. When a patient presents with suspected community-acquired pneumonia, the physician should first assess the need for hospitalization using a mortality prediction tool, such as the Pneumonia Severity Index, combined with clinical judgment. Consensus guidelines from several organizations recommend empiric therapy with macrolides, fluoroquinolones, or doxycycline. Patients who are hospitalized should be switched from parenteral antibiotics to oral antibiotics after their symptoms improve, they are afebrile, and they are able to tolerate oral medications. Clinical pathways are important tools to improve care and maximize cost-effectiveness in hospitalized patients. (*Am Fam Physician* 2006;73:442-50. Copyright © 2006 American Academy of Family Physicians.)

Members of various family medicine departments develop articles for "Practical Therapeutics." This article is one in a series coordinated by the Department of Family Medicine at the University of Illinois at Chicago College of Medicine, Chicago, Ill. Guest editor of the series is Eric Henley, M.D., M.P.H.

Community-acquired pneumonia (CAP) is defined as pneumonia not acquired in a hospital or a long-term care facility. Despite the availability of potent new antimicrobials and effective vaccines,¹ an estimated 5.6 million cases of CAP occur annually in the United States.² The estimated total annual cost of health care for CAP in the United States is \$8.4 billion.² *Table 1* presents an overview of CAP including definition, signs and symptoms, etiology, and risk factors.

Epidemiology

The epidemiology of CAP is unclear because few population-based statistics on the condition alone are available. The Centers for Disease Control and Prevention (CDC) combines pneumonia with influenza when collecting data on morbidity and mortality, although they do not combine them when collecting hospital discharge data. In 2001, influenza and pneumonia combined were the seventh leading causes of death in the United States,^{3,4} down from sixth in previous years, and represented an age-adjusted death rate of 21.8 per 100,000 patients.³ Death

rates from CAP increase with the presence of comorbidity and increased age; the condition affects persons of any race or sex equally. The decrease in death rates from pneumonia and influenza are largely attributed to vaccines for vulnerable populations (e.g., older and immunocompromised persons).

Clinical Presentation

Pneumonia is an inflammation or infection of the lungs that causes them to function abnormally. Pneumonia can be classified as typical or atypical, although the clinical presentations are often similar. Several symptoms commonly present in patients with pneumonia.

TYPES OF CAP

Typical pneumonia usually is caused by bacteria such as *Streptococcus pneumoniae*. Atypical pneumonia usually is caused by the influenza virus, mycoplasma, chlamydia, legionella, adenovirus, or other unidentified microorganism. The patient's age is the main differentiating factor between typical and atypical pneumonia; young adults are more prone to atypical causes,^{5,6} and very

SORT: KEY RECOMMENDATIONS FOR PRACTICE

<i>Clinical recommendation</i>	<i>Evidence rating</i>	<i>References</i>
Patients with suspected community-acquired pneumonia (CAP) should receive chest radiography.	C	8
The Pneumonia Severity Index should be used to assist in decisions regarding hospitalization of patients with CAP.	A	8, 9, 15, 16
The initial treatment of CAP is empiric, and macrolides or doxycycline (Vibramycin) should be used in most patients.	C	8, 9, 29
Respiratory fluoroquinolones should be used when patients have failed first-line regimens, have significant comorbidities, have had recent antibiotic therapy, are allergic to alternative agents, or have a documented infection with highly drug-resistant pneumococci.	C	8, 9, 28, 29

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, see page 374 or <http://www.aafp.org/afpsort.xml>.

young and older persons are more predisposed to typical causes.

SYMPTOMS

Common clinical symptoms of CAP include cough, fever, chills, fatigue, dyspnea, rigors, and pleuritic chest pain. Depending on the pathogen, a patient's cough may be persistent and dry, or it may produce sputum. Other pre-

sentations may include headache and myalgia. Certain etiologies, such as legionella, also may produce gastrointestinal symptoms.

Diagnosis

PHYSICAL EXAMINATION

Physical examination may reveal dullness to percussion of the chest, crackles or rales on auscultation, bronchial breath sounds,

TABLE 1
Overview of Community-Acquired Pneumonia

Definition	Etiology	Risk factors
Lower respiratory tract infection in a nonhospitalized person that is associated with symptoms of acute infection with or without new infiltrate on chest radiographs	Bacterial	Age older than 65 years
	Chlamydia species	Human immunodeficiency virus or immunocompromised
	<i>Haemophilus influenzae</i>	Recent antibiotic therapy or resistance to antibiotics
	Legionella species	Comorbidities
	<i>Moraxella catarrhalis</i>	Asthma
	<i>Mycoplasma pneumoniae</i>	Cerebrovascular disease
	<i>Staphylococcus aureus</i>	Chronic obstructive pulmonary disease
	<i>Streptococcus pneumoniae</i>	Chronic renal failure
	Viral	Congestive heart failure
	Adenovirus	Diabetes
	Influenza A and B	Liver disease
	Parainfluenza	Neoplastic disease
	Respiratory syncytial virus	
	Endemic fungi	
	Blastomycosis	
	Coccidioidomycosis	
	Histoplasmosis	
Clinical presentation		
Temperature greater than 38°C (100.4°F)		
Cough with or without sputum, hemoptysis		
Pleuritic chest pain		
Myalgia		
Gastrointestinal symptoms		
Dyspnea		
Malaise, fatigue		
Rales, rhonchi, wheezing		
Egophony, bronchial breath sounds		
Dullness to percussion		
Atypical symptoms in older patients		

tactile fremitus, and egophony (“E” to “A” changes). The patient also may be tachypneic. A prospective study⁷ showed that patients with typical pneumonia were more likely than not to present with dyspnea and bronchial breath sounds on auscultation.

RADIOGRAPHY

Chest radiography (posteroanterior and lateral views) has been shown to be a critical component in diagnosing pneumonia.⁸ According to

the latest American Thoracic Society (ATS) guidelines for the diagnosis and treatment of adults with CAP, “all patients with suspected CAP should have a chest radiograph to establish the diagnosis and identify complications (pleural effusion, multilobar disease).”⁸ Chest radiography may reveal a lobar consolidation, which is common in typical pneumonia; or it could show bilateral, more diffuse infiltrates than those commonly seen in atypical pneumonia. However, chest radiography performed early in the course of the disease could be negative.

LABORATORY TESTS

Historically, common laboratory tests for pneumonia have included leukocyte count, sputum Gram stain, two sets of blood cultures, and urine antigens. However, the validity of these tests has recently been questioned after low positive culture rates were found (e.g., culture isolates of *S. pneumoniae* were present in only 40 to 50 percent of cases).⁹ Such low positive culture rates are likely due to problems with retrieving samples from the lower respiratory tract, previous administration of antibiotics, contamination from the upper airways, faulty separation of sputum from saliva when streaking slides or plates,⁹ or viral etiology. Furthermore, sputum samples are adequate in only 52.3 percent of patients with CAP, and only 44 percent of those samples contain pathogens.¹⁰ Nonetheless, initial therapy often is guided by the assumption that the presenting disease is caused by a common bacterial pathogen.

Findings¹¹ also cast doubt on the clinical utility of obtaining blood cultures from patients with suspected CAP. In a study¹² of CAP cases in 19 Canadian hospitals over a six-month period, positive blood cultures were obtained in only 5.2 to 6.2 percent of patients, including those with the most severe disease. Based on these findings, other researchers¹³ concluded that a positive blood culture had no correlation with the severity of the illness or outcome. Another prospective study¹⁰ showed that blood cultures were positive in only 10.5 percent of patients with pneumonia. Despite these and

TABLE 2
Sensitivity and Specificity of Diagnostic Tests for CAP

<i>Diagnostic tests by pathogen</i>	<i>Sensitivity (%)</i>	<i>Specificity (%)</i>
Chlamydia		
Rapid PCR (sputum, BAL fluid)	30 to 95	> 95
Serology (fourfold rise in serum and convalescent titers)	10 to 100	—
Sputum culture	10 to 80	> 95
Gram-negative rods		
Sputum Gram stain	15 to 100	11 to 100
<i>Haemophilus influenzae</i>, <i>Moraxella catarrhalis</i>, <i>Pneumoniae</i>		
Sputum culture	Diagnostic yield 20 to 79*	Diagnostic yield 20 to 79*
Influenza		
Rapid DFA (sputum, BAL fluid)	22 to 75	90
<i>Legionella pneumophila</i>		
DFA (sputum, BAL fluid)	22 to 75	90
PCR (sputum, BAL fluid)	83 to 100	> 95
Serum acute titer	10 to 27	> 85
Urinary antigen	55 to 90	> 95
<i>Mycoplasma pneumoniae</i>		
Antibiotic titers	75 to 95	> 90
Cold agglutinins	50 to 60	—
PCR (sputum, BAL fluid)	30 to 95	> 95
<i>Pneumococcal pneumoniae</i>		
Chest radiography (lobar infiltrate)	40†	—
Sputum culture	Diagnostic yield 20 to 79*	Diagnostic yield 20 to 79*
Sputum Gram stain	15 to 100	11 to 100

CAP = community-acquired pneumonia; PCR = polymerase chain reaction; BAL = bronchoalveolar lavage; DFA = direct fluorescence antibody.

*—Overgrowth of oral flora, isolation of atypical agents requires special media.

†—Acute symptoms.

Information from references 2, 8, 11, and 13.

other research findings, current ATS guidelines⁸ recommend that patients hospitalized for suspected CAP receive two sets of blood cultures. Blood cultures, however, are not necessary for outpatient diagnosis.⁸

Legionella antigens were found in the urine of 48 percent of patients with suspected *Legionella pneumophila* serogroup 1 infection.¹⁴ Table 2^{2,8,11,13} includes the sensitivity and specificity of diagnostic tests for CAP.

Treatment

Initial treatment of CAP is based on physical examination findings, laboratory results, and patient characteristics (e.g., age, chronic illnesses, history of smoking, history of the illness).¹⁵ Physicians should begin their treatment decisions by assessing the need for hospitalization using a prediction tool for increased mortality, such as the Pneumonia Severity Index (Table 3¹⁵), combined with clinical judgment.⁹

OUTPATIENT VS. INPATIENT TREATMENT

Choosing between outpatient and inpatient treatment is a crucial decision because of the possible risk of death.^{9,15,16} This decision not only influences diagnostic testing and medication choices, it can have a psychological impact on patients and their families. On average, the estimated cost for inpatient care of patients with CAP is \$7,500. Outpatient care can cost as little as \$150 to \$350.¹⁷⁻¹⁹ Hospitalization of a patient should depend on patient age, comorbidities, and the severity of the presenting disease.^{9,20}

Physicians tend to overestimate a patient's risk of death¹⁴; therefore, many low-risk patients who could be safely treated as outpatients are admitted for more costly inpatient care. The Pneumonia Severity Index (Table 3¹⁵) was developed to assist physicians in identifying patients at a higher risk of complications and who are more likely to benefit from hospitalization.^{9,15,16} Investigators developed a risk model based on a prospective cohort study¹⁶ of 2,287 patients with CAP in Pittsburgh, Boston, and Halifax, Nova Scotia. By using the model, the authors found that 26 to 31 percent of the hospitalized patients were

good outpatient candidates, and an additional 13 to 19 percent only needed brief hospital observation. They validated this model using data¹⁷ from more than 50,000 patients with CAP in 275 U.S. and Canadian hospitals.^{15-17,21,22}

TABLE 3
Pneumonia Severity Index

<i>Patient Characteristics</i>	<i>Points</i>
Demographics	
Male	Age (years)
Female	Age (years) – 10
Nursing home resident	+ 10
Comorbid illness	
Neoplastic disease	+ 30
Liver disease	+ 20
Congestive heart failure	+ 10
Cerebrovascular disease	+ 10
Renal disease	+ 10
Physical examination findings	
Altered mental status	+ 20
Respiratory rate > 30 breaths per minute	+ 20
Systolic blood pressure < 90 mm Hg	+ 20
Temperature < 35°C (95°F) or > 40°C (104°F)	+ 15
Pulse rate > 125 beats per minute	+ 10
Laboratory and radiographic findings	
Arterial pH < 7.35	+ 30
Blood urea nitrogen > 64 mg per dL (22.85 mmol per L)	+ 20
Sodium < 130 mEq per L (130 mmol per L)	+ 20
Glucose > 250 mg per dL (13.87 mmol per L)	+ 10
Hematocrit < 30 percent	+ 10
Partial pressure of arterial oxygen < 60 mm Hg or oxygen percent saturation < 90 percent	+ 10
Pleural effusion	+ 10
<i>Total points:</i> _____	

<i>Point total</i>	<i>Risk</i>	<i>Risk class</i>	<i>Mortality % (No. of patients)</i>	<i>Recommended site of care</i>
No predictors	Low	I	0.1 (3,034)	Outpatient
≤ 70	Low	II	0.6 (5,778)	Outpatient
71 to 90	Low	III	2.8 (6,790)	Inpatient (briefly)
91 to 130	Moderate	IV	8.2 (13,104)	Inpatient
> 130	High	V	29.2 (9,333)	Inpatient

Information from reference 15.

Although the Pneumonia Severity Index can serve as a general guideline for management, clinical judgment should always supersede the prognostic score.⁹

PHARMACOTHERAPY

The primary goals of pharmacotherapy for patients with CAP include eradicating the causative pathogens, resolving the clinical signs and symptoms, minimizing hospitalization, and preventing reinfection.²³⁻²⁷ Physicians should choose a medication based on the pharmacokinetic profile, adverse reactions, drug interactions, and cost-effectiveness.²³⁻²⁷ Further, patient evaluation should focus on severity of illness, patient age, comorbidities, clinical presentation, epidemiologic setting, and previous exposure.⁹ The majority of patients with CAP are treated empirically based on the most common pathogen(s) associated with the condition.²³⁻²⁷

Consensus guidelines from ATS,⁸ Infectious Diseases Society of America,⁹ and Canadian Guidelines for the Initial Management of Community-Acquired Pneumonia²⁸ (Figure 1⁶) recommend initial empiric therapy with macrolides, fluoroquinolones, or doxycycline (Vibramycin). A fourth guideline²⁹ developed by the Therapeutic Working Group of the CDC, however, recommends using fluoroquinolones sparingly because of resistance concerns.

Although data are limited on duration of CAP therapy, current research³⁰ recommends seven to 10 days of therapy for *S. pneumoniae* and 10 to 14 days of therapy for *Mycoplasma pneumoniae* and *Chlamydia pneumoniae*. After a hospitalized patient is clinically stable (i.e., temperature less than 37.8° C [100.0° F], pulse under 100 beats per minute, respiratory rate below 24 breaths per minute, systolic blood pressure above 90 mm Hg, and blood oxygen saturation over 90 percent) and able to tolerate oral intake, the patient may be treated with oral antibiotics for the remainder of the therapy course. This can save money and allow for earlier hospital discharge, which minimizes a patient's risk of hospital-acquired infection.

Figure 1. Algorithm for the management of CAP. (CAP = community-acquired pneumonia.)

Adapted with permission from Fish D. Pneumonia. PSAP, Pharmacotherapy Self-Assessment Program. Kansas City, Mo.: American College of Clinical Pharmacy, 2002:202.

Pneumococcal Resistance

S. pneumoniae, which accounts for 60 to 70 percent of all bacterial CAP cases, can affect all patient groups and can cause a fatal form of CAP. The alarming rate of resistance to many commonly used antibiotics raises great concern. Penicillin-resistant *S. pneumoniae* was uncommon in the early 1990s but has since become increasingly prevalent.^{29,31}

Resistant strains are classified as having intermediate or high-level resistance. Surveillance data in the United States³⁰ revealed that, overall, pneumococcal strains had a 28 percent immediate resistance rate and a 16 percent high-level resistance rate. Decreased susceptibility to other commonly used antibiotics has also been observed (Table 4³²).²⁹⁻³¹ The clinical importance of these data is questionable because recruiting patients infected with resistant pathogens for clinical trials is difficult. Furthermore, available outcomes on the treatment of

TABLE 4
Patterns of Resistance to Antibiotics
in North America*

Antibiotic	Resistance (%)†
Penicillins	
Amoxicillin/clavulanate (Augmentin)	4.1
Penicillin	21.3
Cephalosporins	
Cefepime (Maxipime)	0.4
Cefprozil (Cefzil)	23.9
Ceftriaxone (Rocephin)	1.9
Cefuroxime (Ceftin)	24.7
Macrolides	
Azithromycin (Zithromax)	23.0
Clarithromycin (Biaxin)	26.6
Erythromycin	28.3
Fluoroquinolones	
Gatifloxacin (Tequin)	0.7
Levofloxacin (Levaquin)	0.7
Moxifloxacin (Avelox)	0.4
Miscellaneous	
Clindamycin (Cleocin)	9.2
Tetracycline	18.8
Trimethoprim/sulfamethoxazole (Bactrim, Septra)	29.9
Vancomycin (Vancocin)	0.0

*—Antibiotics tested against *Streptococcus pneumoniae* isolates.

†—Resistance rates averaged across all patient age groups.

Information from reference 32.

pneumonia caused by resistant pneumococcal strains are conflicting.³⁰

The CDC and others recommend outpatient oral empirical antibiotics with a macrolide, doxycycline, or an oral beta-lactam (amoxicillin, cefuroxime [Ceftin], or amoxicillin/clavulanate [Augmentin]) or inpatient treatment with an intravenous beta-lactam (cefuroxime, ceftriaxone [Rocephin], cefotaxime [Claforan]) or a combination of ampicillin/sulbactam (Unasyn) with a macrolide (Figure 1⁶).^{28,29} Conservative use of new fluoroquinolones (levofloxacin [Levaquin], gatifloxacin [Tequin], moxifloxacin [Avelox]) also is recommended to minimize resistance patterns.^{28,29} The new fluoroquinolones (minimum inhibitory concentration: 4 mcg per mL or greater) should be used only when patients have failed recommended

first-line regimens, are allergic to alternative agents, or have a documented infection with highly drug-resistant pneumococci such as those resistant to penicillin.^{28,29}

Cost of Antimicrobial Therapy

Economic pressures have accentuated the focus on reducing health care costs and utilizing resources while maintaining or improving quality of care.³¹ These pressures are exacerbated by the growing resistance of *S. pneumoniae* to penicillin.^{31,32} This pattern of resistance increases the cost of treatment because of prolonged hospitalization, relapses, and the use of more expensive antibacterial agents.³³⁻³⁷

REDUCING COSTS

Numerous methods for reducing costs when treating patients with bacterial infections can be applied to CAP (Table 5). Choosing monotherapy instead of combination therapy

TABLE 5
Strategies for Reducing the Cost
of Antibiotic Therapy

Administration

Use the shortest appropriate course possible.
Switch from parenteral to oral antibiotics as soon as clinically appropriate.

Adverse events

Avoid agents with serious or costly adverse effects.
Avoid agents known to induce resistance.

Drug cost

Compare low impact with total hospital costs (but significant to pharmacy costs).

Hospitalization

Use knowledge of local resistance to initiate early therapy with appropriate spectrum agent (few data available).
Consider availability and cost-effectiveness of intravenous versus oral administration.

Monitoring

Avoid agents that require therapeutic monitoring or laboratory safety tests.

Pharmacotherapy

Use long-acting antibiotics.
Use potent bactericides.
Avoid antibiotics with poor tissue penetration.

TABLE 6
Antimicrobial Therapies for CAP

<i>Agent</i>	<i>Dosage*</i>	<i>Cost per course† (generic)</i>	<i>Common adverse reactions‡</i>
Cephalosporins			Mild diarrhea Rash
Cefotaxime (Claforan)	1 g IV every six to eight hours	\$355 (330)	
Cefpodoxime (Vantin)	200 mg orally twice per day	124 (110)	
Cefprozil (Cefzil)	500 mg orally twice per day	192	
Ceftriaxone (Rocephin)	1 g IV every 24 hours	392	
Cefuroxime (Ceftin)	500 mg orally twice per day	219 oral	
	0.75 to 1.5 g IV every eight hours	250 to 358 IV	
Clindamycins			Mild diarrhea Abdominal pain Pseudomembranous colitis Rash
Clindamycin (Cleocin)	300 mg orally every six hours	238 (148 to 168) oral	
	600 mg IV every eight hours	250 IV	
Fluoroquinolones			Mild diarrhea Nausea Vomiting Constipation Dizziness Headache
Gatifloxacin (Tequin)	400 mg orally or IV once per day	98 oral, 382 IV	
Levofloxacin (Levaquin)	500 mg orally or IV once per day	56 oral, 438 IV	
Moxifloxacin (Avelox)	400 mg orally once per day	107	
Macrolides			Mild diarrhea Nausea Vomiting Abdominal pain Rash
Azithromycin (Zithromax)	500 mg orally for one dose, then 250 mg once per day for four doses	49 to 60 oral	
	500 mg IV every 24 hours	295 IV	
Clarithromycin (Biaxin)	500 mg orally twice per day	96	
Erythromycin	500 mg orally every six hours	17 (8 to 10) oral	
	500 to 1,000 mg IV every six hours	(167) IV	
Penicillins			Mild diarrhea Nausea Vomiting Rash
Amoxicillin	500 mg orally every eight hours	4 (4 to 8)	
	875 mg orally every 12 hours	20 (18 to 19)	
Amoxicillin/clavulanate (Augmentin)	875 mg/125mg orally every 12 hours	166 (110 to 115)	
Penicillin G	1 to 3 mU IV every four hours	(273)	
Penicillin V	500 mg orally four times per day	15 (9 to 15)	
Tetracyclines			Mild diarrhea Nausea Vomiting Phototoxicity
Doxycycline (Vibramycin)	100 mg orally twice per day	102 (16 to 21)	

CAP = community-acquired pneumonia; IV = intravenously.

*—Usual duration for adults with CAP and normal renal function is 10 to 14 days.

†—Estimated cost to the pharmacist based on average wholesale prices in Red Book. Montvale, N.J.: Medical Economics Data, 2005. Cost to the patient will be higher, depending on prescription filling fee.

‡—Adverse events occurring at a rate of approximately 1 to 10 percent.

Adapted with permission from Fish D. *Pneumonia. Pharmacotherapy Self-Assessment Program*. 4th ed. Kansas City, Mo.: American College of Clinical Pharmacy 2002:198.

reduces costs associated with administering an antibacterial.³³⁻³⁷ Using agents with longer half-lives allows for once-daily administration, which in turn leads to improved compliance and outcomes and decreased

costs.³³⁻³⁷ In addition, transitioning patients to oral therapy as soon as they are clinically stable can significantly reduce the length of hospitalization—the major contributing factor to health care costs.³³⁻³⁷

COST-EFFECTIVE CARE

When choosing a treatment, it is essential to compare costs and outcomes of all recommended drug therapies.³¹ *Table 6*⁶ includes the costs of and common adverse reactions to antimicrobial therapies for CAP.

The goal of a formal pharmacoeconomic assessment is to enhance overall patient care using available resources. The evaluation should lead to a decision that will maximize the value of health care services, not simply reduce the costs of drug therapy. For instance, a particular drug may be more expensive, but it may also be more effective, thus lowering overall costs. Another drug may have a higher rate of treatment failures, creating added costs associated with managing the failures. The overall cost of each therapy should be obtained by comparing the end cost with the probability of achieving a positive outcome. Depending on the relative costs associated with treatment failures compared with the costs of cures, the decision to choose one agent over another may change.

The best way to apply cost-saving approaches to the treatment of patients with CAP is by using a clinical pathway.³⁸ This is a method of facilitating multidisciplinary patient care by moving processes of care sequentially through various stages, within specified time frames, toward a desired outcome. These pathways should be specific to each institution, taking into account resistance rates in the community and encouraging the use of the most active, cost-effective agents to produce rapid, positive clinical outcomes.^{31,39}

The authors thank Joel Emery McCullough, M.D., M.S., M.P.H., and Adam Reyburn, M.D., for their assistance in the preparation of the manuscript.

The Authors

M. NAWAL LUTFIYYA, PH.D., is assistant professor and director of research in the Department of Family and Community Medicine at the University of Illinois College of Medicine at Rockford. She also is adjunct assistant professor in the University of Illinois at Chicago (UIC) School of Public Health. Dr. Lutfiyya earned her doctorate at the University of Massachusetts at Amherst after completing other graduate-level training at the University of Iowa, Iowa City.

ERIC HENLEY, M.D., M.P.H., is associate professor and head of the Department of Family and Community Medicine at the University of Illinois College of Medicine at Rockford.

He is an adjunct faculty member in the UIC School of Public Health. Dr. Henley received his medical degree from Georgetown University, Washington, D.C., and completed a family medicine residency at the University of Connecticut School of Medicine, Hartford. He earned his master's in public health at Harvard Medical School, Boston, Mass.

LINDA F. CHANG, PHARM.D., M.P.H., B.C.P.S., is clinical assistant professor in the Department of Family and Community Medicine and the Department of Pharmacy Practice at the University of Illinois College of Medicine at Rockford. She received a doctorate in pharmacy at UIC and completed a general practice pharmacy residency at the Chicago Veterans Administration Hospital.

STEPHANIE WESSEL REYBURN, M.D., M.P.H., is a family practice resident at the Mayo School of Graduate Medical Education, Rochester, Minn. She received her medical degree at the University of Illinois College of Medicine at Rockford and her master's at the UIC School of Public Health.

Address correspondence to M. Nawal Lutfiyya, Ph.D., University of Illinois College of Medicine at Rockford, Department of Family and Community Medicine, 1601 Parkview Ave., Rockford, IL 61107 (email: lutfiyya@uic.edu). Reprints are not available from the authors.

Author disclosure: Nothing to disclose.

REFERENCES

1. Andrews J, Nadjm B, Gant V, Shetty N. Community-acquired pneumonia. *Curr Opin Pulm Med* 2003;9:175-80.
2. Niederman MS. Community-acquired pneumonia: management controversies, part 1; practical recommendations from the latest guidelines. *J Respir Dis* 2002;23:10-7.
3. Arias E, Anderson RN, Kung HC, Murphy SL, Kochanek KD. Deaths: final data for 2001. *Natl Vital Stat Rep* 2003;52:1-115.
4. Hall MJ, DeFrances CJ. 2001 National hospital discharge survey. *Adv Data* 2004;1-20.
5. File TM. Community-acquired pneumonia. *Lancet* 2003;362:1991-2001.
6. Fish D. Pneumonia. In: *Pharmacotherapy self-assessment program*. 4th ed. Kansas City: American College of Clinical Pharmacy, 2002.
7. Beovic B, Bonac B, Kese D, Avsic-Zupanc T, Kreft S, Lesnicar G, et al. Aetiology and clinical presentation of mild community-acquired bacterial pneumonia. *Eur J Clin Microbiol Infect Dis* 2003;22:584-91.
8. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, et al. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. *Am J Respir Crit Care Med* 2001;163:1730-54.
9. Mandell LA, Bartlett JG, Dowell SF, File TM Jr, Musher DM, Whitney C. Infectious Diseases Society of America. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. *Clin Infect Dis* 2003;37:1405-33.
10. Sopena N, Sabria M, Pedro-Botet ML, Manterola JM, Matas L, Dominguez J, et al. Prospective study of

- community-acquired pneumonia of bacterial etiology in adults. *Eur J Clin Microbiol Infect Dis* 1999;18:852-8.
11. Campbell SG, Marrie TJ, Anstey R, Dickinson G, Ackroyd-Stolarz S. The contribution of blood cultures to the clinical management of adult patients admitted to the hospital with community-acquired pneumonia: a prospective observational study. *Chest* 2003;123:1142-50.
12. Feagan BG. A controlled trial of a critical pathway for treating community-acquired pneumonia: the CAPITAL study. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. *Pharmacotherapy* 2001;21(pt 2):S89-94.
13. Priebe DL, Chambliss ML. Blood cultures not helpful for community-acquired pneumonia. *J Fam Pract* 2003;52:599-600.
14. Sopena N, Sabria-Leal M, Pedro-Botet ML, Padilla E, Dominguez J, Morera J, et al. Comparative study of the clinical presentation of Legionella pneumonia and other community-acquired pneumonias. *Chest* 1998;113:1195-200.
15. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. *N Engl J Med* 1997;336:243-50.
16. Fine MJ, Hough LJ, Medsger AR, Li YH, Ricci EM, Singer DE, et al. The hospital admission decision for patients with community-acquired pneumonia. Results from the Pneumonia Patient Outcomes Research Team cohort study. *Arch Intern Med* 1997;157:36-44.
17. Fine MJ, Pratt HM, Obrosky DS, Lave JR, McIntosh LJ, Singer DE, et al. Relation between length of hospital stay and costs of care for patients with community-acquired pneumonia. *Am J Med* 2000;109:378-85.
18. Goss CH, Rubenfeld GD, Park DR, Sherbin VL, Goodman MS, Root RK. Cost and incidence of social comorbidities in low-risk patients with community-acquired pneumonia admitted to a public hospital. *Chest* 2003;124:2148-55.
19. Hoe LK, Keang LT. Hospitalized low-risk community-acquired pneumonia: outcome and potential for cost-savings. *Respirology* 1999;4:307-9.
20. Ruiz M, Ewig S, Marcos MA, Martinez JA, Arancibia F, Mensa J, et al. Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity. *Am J Respir Crit Care Med* 1999;160:397-405.
21. Arnold FW, Ramirez JA, McDonald LC, Xia EL. Hospitalization for community-acquired pneumonia: the pneumonia severity index vs clinical judgment. *Chest* 2003;124:121-4.
22. Roson B, Carratala J, Dorca J, Casanova A, Manresa F, Gudiol F. Etiology, reasons for hospitalization, risk classes, and outcomes of community-acquired pneumonia in patients hospitalized on the basis of conventional admission criteria. *Clin Infect Dis* 2001;33:158-65.
23. Mandell LA. Community-acquired pneumonia. Etiology, epidemiology, and treatment. *Chest* 1995;108(suppl):S35-42.
24. Mandell LA. Antibiotic therapy for community-acquired pneumonia. *Clin Chest Med* 1999;20:589-98.
25. Mandell LA. Antimicrobial approaches to therapy for pneumonia. *Curr Opin Pulm Med* 1996;2:218-27.
26. Mundy LM, Oldach D, Auwaerter PG, Gaydos CA, Moore RD, Bartlett JG, et al., for the Hopkins CAP team. Implications for macrolide treatment in community-acquired pneumonia. *Chest* 1998;113:1201-6.
27. Mandell LA. Antibiotics for pneumonia therapy. *Med Clin North Am* 1994;78:997-1014.
28. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH, for the Canadian Community-Acquired Pneumonia Working Group. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. *Clin Infect Dis* 2000;31:383-421.
29. Heffelfinger JD, Dowell SF, Jorgensen JH, Klugman KP, Mabry LR, Musher DM, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant *Streptococcus pneumoniae* Working Group. *Arch Intern Med* 2000;160:1399-408.
30. Mandell LA, Bergeron MC, Gribble MJ, et al. Sequential antibiotic therapy: effective cost management and patient care. *Can J Infect Dis* 1995;6:306.
31. Kuti JL, Capitano B, Nicolau DP. Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance. *Pharmacoeconomics* 2002;20:513-28.
32. Jones RN, Biedenbach DJ, Beach ML. Influence of patient age on the susceptibility patterns of *Streptococcus pneumoniae* isolates in North America (2000-2001): report from the SENTRY Antimicrobial Surveillance Program. *Diagn Microbiol Infect Dis* 2003;46:77-80.
33. Begg EJ, Barclay ML, Kirkpatrick CM. The therapeutic monitoring of antimicrobial agents. *Br J Clin Pharmacol* 2001;52(suppl 1):S35-43.
34. Milkovich G. Intravenous-to-oral transition therapy in community-acquired pneumonia: the INOVA Health System experience. *Pharmacotherapy* 2001;21(pt 2):S83-8.
35. Weingarten SR, Riedinger MS, Varis G, Noah MS, Belman MJ, Meyer RD, et al. Identification of low-risk hospitalized patients with pneumonia. Implications for early conversion to oral antimicrobial therapy. *Chest* 1994;105:1109-15.
36. Siegel RE, Halpern NA, Almenoff PL, Lee A, Cashin R, Greene JG. A prospective randomized study of in-patient iv. antibiotics for community-acquired pneumonia. The optimal duration of therapy. *Chest* 1996;110:965-71.
37. Ramirez JA, Vargas S, Ritter GW, Brier ME, Wright A, Smith S, et al. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. *Arch Intern Med* 1999;159:2449-54.
38. Coffey RJ, Richards JS, Remmert CS, LeRoy SS, Schoville RR, Baldwin PJ. An introduction to critical paths. *Qual Manag Health Care* 1992;1:45-54.
39. Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vanervoort MK, Feagan BG. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. *JAMA* 2000;283:749-55.